𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Immune responses of DBA/2 mice bearing melanoma tumors: Cell-mediated immune responses after challenge with vaccinia virus

✍ Scribed by Jacquelyn A. Byrne; M. Soloski; J. A. Holowczak

Publisher
Springer-Verlag
Year
1983
Tongue
English
Weight
851 KB
Volume
16
Category
Article
ISSN
0340-7004

No coin nor oath required. For personal study only.

✦ Synopsis

Splenic lymphocytes from TB-mice had a reduced capacity to respond to both B and T-cell mitogens, but TB-mice responded to infection with vaccinia virus by developing a virus-specific cytotoxic T-cell response equal to that measured with splenic effectors prepared from virus-infected C-mice. NK-cell activity,

as measured by the in vitro lysis of YAC-1 targets by splenic effectors, was significantly depressed in TB-mice but, after infection of the animals with vaccinia virus, was restored to levels equal to that measured with splenic effectors prepared from C-mice. Doses of vaccinia virus, strain WR which elicited vaccinia-virus-specific cytotoxic T cells or stimulated NK-ceU activity, failed to elicit or stimulate cytotoxic effectors specific for S91-melanoma tumor cells.

πŸ“œ SIMILAR VOLUMES

Immune responses in mice to tumour chall
Immune responses in mice to tumour challenge after immunization with newcastle disease virus-infected or X-irradiated tumour cells or cell fractions
✍ P. C. L. Beverley; R. M. Lowenthal; D. A. J. Tyrrell πŸ“‚ Article πŸ“… 1973 πŸ› John Wiley and Sons 🌐 French βš– 803 KB

## Abstract Cells of the transplantable ascites tumour sarcoma 37 (S37) have been infected __in vitro__ with Newcastle disease virus (NDV). Infected cells, a virus‐containing fraction of such cells, and X‐irradiated S37 cells have been found to immunize mice against subsequent tumour challenge. Ant

Tumor metastases and cell-mediated immun
Tumor metastases and cell-mediated immunity in a model system in DBA/2 mice. V. Transfer of protective immunity with H-2 identical immune T cells from B10.D2 mice
✍ V. Schirrmacher πŸ“‚ Article πŸ“… 1979 πŸ› John Wiley and Sons 🌐 French βš– 683 KB

## Abstract Evidence is presented for the existence of immune T lymphocytes which have protective activity __in vivo__ against the lethal effects of a metastasizing tumor. ESb, the metastasizing tumor cell line of our model system, which is highly malignant in syngeneic DBA/2 mice, can be rejected

Melphalan-mediated potentiation of antit
Melphalan-mediated potentiation of antitumor immune responsiveness of immunosuppressed spleen cells from mice bearing a large MOPC-315 tumor
✍ Robert C. Bocian; Shlomo Ben-Efraim; Sheldon Dray; Margalit B. Mokyr πŸ“‚ Article πŸ“… 1984 πŸ› Springer-Verlag 🌐 English βš– 927 KB

Administration of a low dose of L-PAM (0.75 mg/kg) to mice bearing a large SC MOPC-315 tumor and extensive metastases led to the development of augmented antitumor immune potential in their hitherto immunosuppressed spleen cells. Such drug-induced potentiation of antitumor immune responsiveness appe

Suppression of immune response to sheep
Suppression of immune response to sheep red blood cells in mice treated with preparations of a tumor cell component and in tumor-bearing mice
✍ Mary A. Pikovski; Y. Ziffroni-Gallon; I. P. Witz πŸ“‚ Article πŸ“… 1975 πŸ› John Wiley and Sons 🌐 English βš– 410 KB πŸ‘ 1 views

## Abstract The frequency of rosette‐forming cells (RFC) in spleens of mice immunized with sheep red blood cells (SRBC) was significantly reduced by pretreatment with preparations obtained from tumor extracts. This effect was not produced by preparations obtained by similar methods from normal tiss

Immunity against moloney sarcoma virus i
Immunity against moloney sarcoma virus in H-2Db mutant bm14 mice. Unimpaired tumor immunity despite absence of a virus-specific cytotoxic T-cell response
✍ Marijke J. Stukart; Jolande Boes; Cornelis J. M. Melief πŸ“‚ Article πŸ“… 1984 πŸ› John Wiley and Sons 🌐 French βš– 501 KB

It was shown previously that B6.C-H-Zbm" (bm14) mice, carrying a mutation in the H-2Db locus, are unable to generate cytotoxic T cells (CTL) against Moloney murine sarcoma virus (M-MSV). We now report an analysis of tumor induction and regression kinetics and of immunity to the virus, following the